Drug Combination Details
| General Information of the Combination (ID: C03179) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Lenalidomide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BC-3 | CVCL_1080 | Primary effusion lymphoma | Homo sapiens | ||
| BCBL-1 | CVCL_0165 | Primary effusion lymphoma | Homo sapiens | |||
| In-vivo Model | Six to eight week old immuno-compromised male or female NOD/SCID mice were inoculated with 2 million BC-3 or BCBL-1 cells. | |||||
| Experimental
Result(s) |
Lenalidomide in combination with arsenic trioxide is an effective therapy for primary effusion lymphoma. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma. Cancers (Basel). 2020 Sep 1;12(9):2483. | |||
